FORMULATION AND EVALUATION OF VILDAGLIPTIN 100 MG SUSTAINED-RELEASE TABLETS BY USING POLYELECTROLYTE COMPLEX

The goal of the current study was to Formulate Vildagliptin sustained release tablets by using Polyelectrolyte complex. Vildagliptin has very short half-life ie. (2–3 hours), therefore this medication is thought to be appropriate for sustained release tablet formulation, in order to extend its therapeutic effect. The Vildagliptin is a novel dipeptidyl peptidase-4 inhibitor class of oral anti-hyperglycemic medication. And this is drug of choice for the treatment of type 2 diabetes mellitus. The present study was carried out to evaluate the inter-polymer complex formed with Eudragit E100 and Eudragit L100 as a sustained release tablets for water soluble Vildagliptin. In this study six trials formulation was prepared .all the six trial contains equal amount of drug with IPE Complex and it Shows better results in all evaluation parameters amongst the all trials the trial F6 is better formulation and formulation F6 has better compatibility with all Excipients and has better dissolution profile as compared to all five (FI TO F5) formulations and formulation F6 has drug content uniformity is 99.21%, which was high as compared to all formulations and percentage drug release from polyelectrolyte complex is 98.87%. Among all the six trials with the physical mixtures, the one with the 1:1 ratios was found to be the best as compared to all other ratios and it is given controlled release profile as per USP limits.